Acrivon Therapeutics, Inc. Common Stock (ACRV) NASDAQ
1.98
+0.0092(+0.47%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.98
+0.0092(+0.47%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.98 |
| Day High | 2 |
| Day Low | 1.93 |
| 52-Week High | 3.56 |
| 52-Week Low | 1.05 |
| Volume | 173,323.63 |
| Average Volume | 850,113 |
| Market Cap | 62.46M |
| PE | -0.98 |
| EPS | -2.02 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 1.78 |
| Change | 0.01 |
Data not available
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gen
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently di
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partn